[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-359189-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-359189-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","risk-of-intestinal-cancer-in-crohns-disease-re-analysis-and-meta-regression-of-population-based-cohort-studies","Risk of intestinal cancer in Crohn’s disease - re-analysis and meta-regression of population-based cohort studies","","Background and aims: The risk of intestinal malignancy in Crohn’s disease (CD) varies across regions. With cancer prevalence increasing globally, this study summarizes evidence and tests associations between CD and site-specific intestinal cancer risks. Methods: PubMed, Embase, and Scopus were searched from inception to July 10, 2025, including adult population-based cohorts reporting observed and expected national cases. Exclusions included early post-diagnosis CRC/SBC and non-eligible designs. Results: Elevated CRC and especially SBC risks were found, with variation by disease location. Meta-regression assessed cohort size, follow-up, calendar year, and location effects.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/risk-of-intestinal-cancer-in-crohns-disease-re-analysis-and-meta-regression-of-population-based-cohort-studies/359189/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/risk-of-intestinal-cancer-in-crohns-disease-re-analysis-and-meta-regression-of-population-based-cohort-studies/359189.png","ImageObject",300,407,{"name":42,"@type":43},"Mia  ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-18","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the primary aim of this study on Crohn’s disease and cancer risk?","Question",{"text":63,"@type":64},"To summarize evidence and evaluate associations between Crohn’s disease and site-specific intestinal cancer risks across regions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which studies were included, and what key criteria led to exclusions?",{"text":68,"@type":64},"Included studies were population-based epidemiological observational studies in adults reporting observed and expected national cases. Excluded were studies on CRC/SBC occurring less than 1 year after CD diagnosis, mortality papers combining CD and ulcerative colitis, referral-center studies, and review articles.",{"name":70,"@type":61,"acceptedAnswer":71},"How did cancer risk estimates vary by cancer type and disease location?",{"text":72,"@type":64},"CRC risk was significantly elevated with higher risks for colon and rectal cancer, and particularly in colonic and ileocolonic disease. Small bowel cancer risk showed a much larger increase, especially for ileal and ileocolonic disease.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},359189,1790482089,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Risk of intestinal cancer in Crohn’s disease: re-analysis and meta-regression of population-based cohort studies  \nEnrico Altiero Giusto*, 1,2,, Paolo Pinton*, 1,3, Carlotta Giorgi1,4,, Grazia Serino5,, Gianluigi Giannelli5,, Rossella Donghia5,, Francesco Fiorica6,7,  \n1Department of Medical Sciences, Section of Experimental Medicine and Laboratory of Technologies for Advanced Therapy (LTTA), University of Ferrara, Ferrara, Italy  \n2Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy 3Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy  \n4 Biomedical Research Center, Kansai Medical University, Osaka, Japan  \n5 National Institute of Gastroenterology—IRCCS “Saverio de Bellis,” Castellana Grotte, Italy 6Department of Clinical Oncology, Section of Radiation Oncology and Nuclear Medicine, Verona, Italy 7Department of Clinical Oncology, Section of Medical Oncology, Verona, Italy  \n*Corresponding authors: Enrico Altiero Giusto, Department of Medical Sciences, Section of Experimental Medicine and Laboratory of Technologies for Advanced Therapy (LTTA), University of Ferrara, Ferrara, Italy ([enricoaltiero.giusto@edu.unife.it](enricoaltiero.giusto@edu.unife.it); [gstncl@unife.it](gstncl@unife.it)) and Paolo Pinton, Department of Medical  \nSciences, Section of Experimental Medicine and Laboratory of Technologies for Advanced Therapy (LTTA), University of Ferrara, Ferrara, Italy ([paolo.pinton@unife.it](paolo.pinton@unife.it)) .  \nAuthor Contributions: Enrico Altiero Giusto and Paolo Pinton shared co-first authorship.  \nAbstract  \nBackground and aims: The risk of intestinal malignancy in Crohn’s disease (CD) varies across regions. Given the rising global cancer prevalence, this study aimed to summarize evidence and evaluate associations between CD and site-specific intestinal cancer risks.  \nMethods: We systematically searched PubMed, Embase, and Scopus from inception to July 10, 2025. All population-based epidemiological observational studies that investigated any outcome related to intestinal cancer in adults (the majority of participants >18 years of age), including individuals of any ethnicity or sex from all countries and settings that report observed and expected national cases, were included. Patients diagnosed with colorectal cancer (CRC) or small bowel cancer (SBC) less than 1 year after CD diagnosis, as well as papers that address cancer mortality while combining CD and ulcerative colitis outcomes, referral-center studies, and review articles, were excluded. We analyzed 27 population-based studies using restricted maximum-likelihood models; pooled standardized incidence ratios (SIRs) were calculated for CRC and SBC. Meta-regression explored the impact of cohort size, follow-up duration, calendar year, and disease location on risk estimates. Methodological quality was assessed with the modified Newcastle–Ottawa Scale.  \nResults: The overall CRC SIR in CD patients was significantly elevated (SIR 2.20, 95% CI 1.69-2.86) . Colon cancer (SIR 2.06, 95% CI 1.09-3.90) and rectal cancer (SIR 1.75, 95% CI 1.16-2.62) risks were higher, especially in colonic disease (SIR 3.29, 95% CI 1.66-6. 50) and ileocolonic disease (SIR 4. 13, 95% CI 2.14-7.94), while ileal disease exposed a milder risk (SIR 1.95, 95% CI 1.16-3.26) . SBC SIR was markedly increased (SIR 17. 18, 95% CI 9.93-29.73), particularly in ileal (SIR 44.85, 95% CI 12.93-155. 54) and ileocolonic disease (SIR 21.44, 95% CI 5.13-89.62) .  \nConclusion: CD is associated with heightened CRC and SBC risks, varying by disease location. These findings underscore the need for tailored cancer screening and further research into the impact of environmental and genetic factors on cancer risk in CD patients.  \nKey words: neoplasms; Crohn's disease; intestine; inflammatory bowel disease.  \n© The Author(s) 2026. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.  \nThis is an Open Access article distributed under the terms of the Creative C","cbCaioOOV52AVtP8","https://ap.wps.com/l/cbCaioOOV52AVtP8","pdf",2891759,13,"English","# Abstract\n## Background and aims\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the primary aim of this study on Crohn’s disease and cancer risk?\",\"answer\":\"To summarize evidence and evaluate associations between Crohn’s disease and site-specific intestinal cancer risks across regions.\"},{\"question\":\"Which studies were included, and what key criteria led to exclusions?\",\"answer\":\"Included studies were population-based epidemiological observational studies in adults reporting observed and expected national cases. Excluded were studies on CRC/SBC occurring less than 1 year after CD diagnosis, mortality papers combining CD and ulcerative colitis, referral-center studies, and review articles.\"},{\"question\":\"How did cancer risk estimates vary by cancer type and disease location?\",\"answer\":\"CRC risk was significantly elevated with higher risks for colon and rectal cancer, and particularly in colonic and ileocolonic disease. Small bowel cancer risk showed a much larger increase, especially for ileal and ileocolonic disease.\"}]","Risk of intestinal cancer in Crohn’s disease - re-analysis and meta-regression of population-based cohort studies | PDF",1790136373,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c2b48f3dd26d491140da7b1b9f8207b.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac2f0a5494cec70e380a967c5df29de5.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09f8fdfa3623ea7c5ec3ea603add3071.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/817a7d65835592ad55895a394f1697b6.webp",980,1287]